Dataset from A Randomized, Double-blind, Parallel Group, Placebo Controlled, Multi-center Study of Fixed Dose Combinations of Solifenacin Succinate (6 mg and 9 mg) With Tamsulosin Hydrochloride OCAS 0.4 mg and Tamsulosin Hydrochloride OCAS 0.4 mg Monotherapy, in Male Subjects With Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH) With a Substantial Storage Component

Clinical study to examine the efficacy, safety and tolerability of combination therapy of tamsulosin hydrochloride and solifenacin succinate compared to monotherapy of tamsulosin hydrochloride in the treatment of males with LUTS associated with BPH with a substantial storage component.

本临床研究旨在评估盐酸坦索罗辛（tamsulosin hydrochloride）与琥珀酸索利那新（solifenacin succinate）联合疗法，相较于单纯使用盐酸坦索罗辛的单药疗法，治疗伴有显著储尿期症状的良性前列腺增生（Benign Prostatic Hyperplasia, BPH）相关性下尿路症状（Lower Urinary Tract Symptoms, LUTS）男性患者的疗效、安全性及耐受性。